AbCellera Biologics Inc. (ABCL) financials
NASDAQ · Healthcare · Biotechnology · 562 employees · CEO Carl Hansen
- Price
- $12.27 -6.19%
- Market cap
- $3.98B
- Enterprise value
- $3.99B
- Last report
- Q2 '26 filed 2026-08-05
- Next report
- 2026-11-09
Revenue (TTM)$66.2M+101.3% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)-340.3%+507.4 pp vs a year agoOperating income -$225M
Net income (TTM)-$165M+0.6% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)-$179M-28.9% vs a year agoCapex $24.7M
Diluted EPS (TTM)-$0.54+3.6% vs a year agoSum of the last 4 quarters
Net cash$404M-1.6% vs a year agoCash + short-term investments - debt
Valuation & key figures
- Market cap
- $3.98B EV $3.99B
- Revenue
- $66.2M Trailing 12 months
- Revenue growth
- – Next fiscal year
- Profit margin
- -248.8% Net income / revenue, TTM
- P/E
- -22.7×
- P/S
- 60.1× Price / sales, TTM
- EV / EBITDA
- -23.6× TTM
- Free cash flow
- -$179M Trailing 12 months
- Net income
- -$165M Trailing 12 months
- Revenue estimate
- – Next fiscal year
- Earnings
- 2026-11-09
- Dividend
- – No dividend
Key takeaways
Computed from the reported numbers - every statement carries the figure it rests on.
- Last report (2026-08-05): revenue missed by 48.4%, EPS missed by 9.8%Revenue $4.05M vs $7.85M expected (-48.4%); EPS -$0.18 vs -$0.16 (-9.8%).
- Revenue growth slowing: -76.3% year on yearQ2 '26 revenue $4.05M, against an average of 263.9% over the four quarters before.
- Operating margin -340.3% (TTM), +507.4 pp on a year agoOperating income grew 19.2% while revenue grew 101.3%.
- Capex 37.4% of revenue (a year ago 177.1%)$24.7M invested in the last 4 quarters (-57.5% on a year earlier). Free cash flow -$179M.
- Diluted share count up 2.4% in a year306M diluted shares in Q2 '26, 299M a year earlier.
- Net cash $404MCash + short-term investments $540M, debt incl. leases $136M; a year ago net cash $411M.
Last quarter: Q2 '26
Quarter ended 2026-06-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.
Quarter vs a year ago
| Q2 '26 | Year ago | Change | |
|---|---|---|---|
| Revenue | $4.05M | $17.1M | -76.3% |
| Gross margin | 100.0% | 100.0% | 0.0 pp |
| Operating income | -$62.8M | -$49.6M | -26.6% |
| Operating margin | -1,550.0% | -290.2% | -1,259.8 pp |
| Net income | -$55.4M | -$34.7M | -59.6% |
| Diluted EPS | -$0.18 | -$0.12 | -50.0% |
| Operating cash flow | -$33.9M | -$32.4M | -4.5% |
| Capex | $2.13M | $13.4M | -84.0% |
| Free cash flow | -$36M | -$45.8M | +21.4% |
| R&D | $46M | $39.2M | +17.3% |
| Stock-based compensation | $12.3M | $14.2M | -13.5% |
Reported vs consensus
2026-08-05| Actual | Consensus | vs consensus | |
|---|---|---|---|
| Revenue | $4.05M | $7.85M | -48.4% |
| EPS (as estimated) | -$0.18 | -$0.16 | -9.8% |
From the report of 2026-08-05 for Q2 '26: revenue and the EPS analysts estimate (often adjusted), so it can differ from the EPS of the statements above.
EPS vs consensus
last 8 reportsRevenue
Where the money comes from - by business line and by region, quarter by quarter.
Revenue, operating income and growth
quarterlyRevenue by business line
stacked, quarterly| Segment | Q2 '26 | y/y | Share | TTM | TTM y/y | 12 quarters |
|---|---|---|---|---|---|---|
| License | – | – | – | – | – | |
| Research Fees | $3.9M | -41.2% | 96.3% | $28.5M | +4.8% | |
| Licensing and Royalty Revenue | $149K | – | 3.7% | – | – |
Margins & cost structure
How much of each unit of revenue is left at each level - and where the costs go.
Margins
quarterlyCosts as % of revenue
quarterlyCash flow & capital allocation
Cash generated, what it is spent on, and what reaches shareholders.
Operating cash flow, capex, free cash flow
quarterlyUses of cash vs operating cash flow
fiscal yearsLast 4 quarters
cash flow statement- Operating cash flow
- -$155M
- Capex
- -$24.7M
- Buybacks
- $0
- Dividends
- $0
- Acquisitions
- -$5M
- Net debt issued
- $25.3M
- Stock-based compensation
- $51.1M
- Free cash flow
- -$179M
- Returned to shareholders / FCF
- 0.0%
Share count and EPS
quarterly, dilutedBalance sheet
Liquidity, investments and debt at each quarter end.
Cash, investments and debt
quarter endsValuation & returns
Today's multiples against the company's own last five fiscal years; analyst targets and ratings.
Multiples and returns
TTM vs 5 fiscal years| Now | 5y average | Where today sits in the 5-year range | |
|---|---|---|---|
| P/E (TTM) | -22.7× | 21.8× 2 of 5 years | 18.1× – 25.5× |
| EV / EBITDA | -23.6× | 12.3× 2 of 5 years | 9.9× – 14.7× |
| EV / Sales | 60.3× | 19.4× | 5.3× – 42.0× |
| Price / FCF | -22.2× | 17.6× 2 of 5 years | 14.1× – 21.2× |
| Price / Book | 4.2× | 1.9× | 0.8× – 3.8× |
| FCF yield | -4.5% | -6.9% | -21.7% – 7.1% |
| Return on invested capital | -15.0% | -5.2% | -19.9% – 11.9% |
| Return on equity | -17.5% | -3.1% | -15.4% – 15.0% |
Analysts
Consensus target $16.33 (+33.1%)
range $7.00 – $30.00 · rating Buy
Strong buy0
Buy11
Hold1
Sell0
Strong sell0
Financial statements
Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.
Every reported line
All 173 figures AbCellera Biologics Inc. tagged in its recent 10-Q / 10-K filings, with the official SEC label and definition - including the notes (leases, taxes, buybacks, employees, ...).
| Line (SEC label) | Latest quarter | Year ago | y/y | Latest FY | Prior FY | y/y |
|---|---|---|---|---|---|---|
| Accounts Payable and Accrued Liabilities, Current | $12.1M | $32M | -62.2% | $25.2M | $34.4M | -26.6% |
| Accounts Payable and Other Accrued Liabilities, Current | $32.5M | $50.1M | -35.1% | $50.8M | $55M | -7.7% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$3.15M | -$2.66M | -18.6% | -$4.23M | -$4.38M | +3.3% |
| Additional Paid in Capital, Common Stock | $206M | $181M | +13.5% | $198M | $166M | +19.2% |
| Amortization of Intangible Assets | $931K | $929K | +0.2% | $3.7M | $14.3M | -74.1% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 76.2M | 71.7M | +6.2% | 70.9M | 58.3M | +21.8% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $12.3M | $14.4M | -14.7% | $56.3M | $67.6M | -16.7% |
| Assets | $1.31B | $1.4B | -6.7% | $1.36B | $1.36B | -0.3% |
| Assets, Current | $679M | $742M | -8.5% | $728M | $751M | -3.1% |
| Assets, Noncurrent | $628M | $660M | -4.8% | $629M | $609M | +3.2% |
| Business Combination, Contingent Consideration, Liability, Current | $02025-12-31 | $8.09M | -100.0% | $0 | $8.09M | -100.0% |
| Cash | $99.3M2025-12-31 | $127M | -21.9% | $99.3M | $127M | -21.9% |
| Cash and Cash Equivalents, at Carrying Value | $120M | $92.4M | +29.9% | $129M | $156M | -17.8% |
| Cash and Cash Equivalents, at Carrying Value | 61,800,000 CAD2025-12-31 | 55,600,000 CAD | +11.2% | 61,800,000 CAD | 55,600,000 CAD | +11.2% |
| Cash Equivalents, at Carrying Value | $29.3M2025-12-31 | $29.2M | +0.3% | $29.3M | $29.2M | +0.3% |
| Cash, Cash Equivalents, and Short-term Investments | $540M | $553M | -2.3% | $534M | $626M | -14.7% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $145M | $117M | +23.5% | $154M | $181M | -15.3% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | $147M | $120M | +22.8% | $155M | $184M | -15.4% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $43.2M | -$66.8M | +164.7% | -$28.4M | $23M | -223.3% |
| Common Stock, No Par Value | $0.00 | $0.00 | – | $0.00 | $0.00 | – |
| Common Stock, Par or Stated Value Per Share | $0.002025-12-31 | $0.00 | – | $0.00 | $0.00 | – |
| Common Stock, Shares, Issued | 306M | 296M | +3.6% | 301M | 296M | +1.6% |
| Common Stock, Shares, Outstanding | 306M | 296M | +3.6% | 301M | 296M | +1.6% |
| Common Stock, Value, Issued | $821M | $792M | +3.7% | $802M | $777M | +3.2% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$56.2M | -$30.4M | -84.8% | -$146M | -$166M | +11.6% |
| Contract with Customer, Liability | $61.2M | $28.6M | +114.0% | $17M | $19.2M | -11.4% |
| Contract with Customer, Liability, Current | $20.7M | $16.9M | +22.2% | $13.5M | $13.5M | 0.0% |
| Contract with Customer, Liability, Noncurrent | $40.5M | $11.6M | +247.7% | $5.7M2024-12-31 | $8.2M | -30.4% |
| Contract with Customer, Liability, Revenue Recognized | $3.7M | $4.1M | -9.8% | $11.8M | $20.6M | -42.7% |
| Current Federal Tax Expense (Benefit) | – | – | – | -$30M | -$18.5M | -62.8% |
| Current Foreign Tax Expense (Benefit) | – | – | – | -$201K | $671K | -130.0% |
| Current Income Tax Expense (Benefit) | – | – | – | -$30.2M | -$17.8M | -70.0% |
| Debt Securities, Available-for-sale | $420M | $461M | -8.8% | $405M | $469M | -13.6% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | $0 | $749K | -100.0% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | -$938K | -$20.5M | +95.4% |
| Deferred Income Tax Liabilities, Net | $9.12M2025-12-31 | $10.1M | -9.3% | $9.12M | $10.1M | -9.3% |
| Deferred Tax Assets, Gross | $135M2025-12-31 | $104M | +30.2% | $135M | $104M | +30.2% |
| Deferred Tax Assets, Operating Loss Carryforwards | $2.13M2025-12-31 | $15.6M | -86.4% | $2.13M | $15.6M | -86.4% |
| Deferred Tax Assets, Operating Loss Carryforwards, Foreign | $4.8M2025-12-31 | $17.9M | -73.2% | $4.8M | $17.9M | -73.2% |
| Deferred Tax Assets, Other | $1.06M2025-12-31 | $5.39M | -80.3% | $1.06M | $5.39M | -80.3% |
| Deferred Tax Assets, Tax Credit Carryforwards, Research | $56M2025-12-31 | $33.6M | +67.0% | $56M | $33.6M | +67.0% |
| Deferred Tax Assets, Valuation Allowance | $56.2M2025-12-31 | $49.9M | +12.7% | $56.2M | $49.9M | +12.7% |
| Deferred Tax Liabilities, Gross | $87.7M2025-12-31 | $63.7M | +37.7% | $87.7M | $63.7M | +37.7% |
| Deferred Tax Liabilities, Intangible Assets | $8.65M2025-12-31 | $9.59M | -9.9% | $8.65M | $9.59M | -9.9% |
| Deferred Tax Liabilities, Net | $9.12M2025-12-31 | $10.1M | -9.3% | $9.12M | $10.1M | -9.3% |
| Deferred Tax Liabilities, Other | $11.7M2025-12-31 | $17.5M | -32.7% | $11.7M | $17.5M | -32.7% |
| Deferred Tax Liabilities, Property, Plant and Equipment | $30.6M2025-12-31 | $20.8M | +47.2% | $30.6M | $20.8M | +47.2% |
| Depreciation | $6.1M | $4.6M | +32.6% | $18.4M | $12.5M | +47.1% |
| Depreciation, Depletion and Amortization | $6.99M | $5.47M | +27.8% | – | – | – |
| Depreciation, Depletion and Amortization, Nonproduction | $5.25M2025-09-30 | $36.9M | -85.8% | $24.4M2023-12-31 | $27.8M | -12.4% |
| Dividends | – | – | – | $0 | $0 | – |
| Dividends, Cash | – | – | – | $0 | $0 | – |
| Earnings Per Share, Basic | -$0.18 | -$0.12 | -50.0% | -$0.49 | -$0.55 | +10.9% |
| Earnings Per Share, Diluted | -$0.18 | -$0.12 | -50.0% | -$0.49 | -$0.55 | +10.9% |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | -$430K | $761K | -156.5% | $1.1M | -$2.62M | +141.9% |
| Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | – | – | – | -$54.1M2024-12-31 | -$47M | -15.2% |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | – | – | – | 27.0%2024-12-31 | 27.0% | 0.0% |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | – | – | – | $12.3M | $15.2M | -19.0% |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | – | – | – | -6.9% | – | – |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | – | – | – | $11.9M | – | – |
Source: SEC companyfacts (XBRL of every 10-Q / 10-K). Cash-flow quarters are derived from the year-to-date figures the 10-Q tags. Segment breakdowns are tagged with dimensions and are shown in the segment section instead.
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data as of 2026-11-02